Nasdaq

Medtronic announces first patient implants of investigational implantable tibial neuromodulation therapy for bladder incontinence

DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate ...
Nasdaq

Medtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence

New Investigational Device Aims to Expand Access to Therapy for Patients with Incontinence; Underscores Medtronic's Leadership as Only Company to Offer Neuromodulation Options for Incontinence DUBLIN, ...
BioWorld

Medtronic implants neuromodulation device in first patients with overactive bladder

Medtronic plc reported its tibial neuromodulation device was implanted in the first patient with overactive bladder as part of its Titan 2 pivotal study. The device stimulates the posterior tibial ...
AOL

Medtronic ratchets up patent spat for device that aids in bladder, bowel control

Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
FierceBiotech

Medtronic kicks off pivotal study of tibial neuromodulation implant for overactive bladder

Medtronic said a tibial neuromodulation device would be less invasive compared to sacral implants, which are considered the current standard of care. (Medtronic) After receiving an FDA approval last ...
BioWorld

Minze, Medtronic partner on overactive bladder care in EMEA

Minze Health NV signed a three-year agreement with Medtronic plc to bring its Minze Diary Pod, an app-controlled automated urine collection device, to markets across the EMEA region. The partnership ...